Table 1.

Safety and Efficacy of Biologics for Immune Checkpoint Inhibitor-Induced Bullous Pemphigoid

Author	Cancer Type	Age	Gender	Dosage	Clinical Efficacy	Tumor Progression	Follow-up Duration	Study Type
Klepper et al28	Lung Cancer	68	F	Dupilumab	Rapid disease control, symptom resolution	Not applicable	5 months	Case Report
Schauer et al30	Various cancers	50–80	M/F	Rituximab,	Clinical improvement	Not applicable	12 months	Retrospective Study
Fournier et al31	Various cancers	60–75	M/F	Dupilumab	Successful treatment of BP	Remission or Death from cancer progression	3–6 months	Case Series
Yun et al32	Various cancers	55–78	M/F	Rituximab, Omalizumab	Adequate control of BP	Increased tumor progression in some patients	6–18 months	Case Series